CA2628390A1 - Profilage moleculaire de cancer - Google Patents

Profilage moleculaire de cancer Download PDF

Info

Publication number
CA2628390A1
CA2628390A1 CA002628390A CA2628390A CA2628390A1 CA 2628390 A1 CA2628390 A1 CA 2628390A1 CA 002628390 A CA002628390 A CA 002628390A CA 2628390 A CA2628390 A CA 2628390A CA 2628390 A1 CA2628390 A1 CA 2628390A1
Authority
CA
Canada
Prior art keywords
cancer
expression
cancer marker
prostate
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002628390A
Other languages
English (en)
Inventor
Arul Chinnaiyan
Sooryanarayana Lnu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan
Original Assignee
The Regents Of The University Of Michigan
Arul Chinnaiyan
Sooryanarayana Lnu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of Michigan, Arul Chinnaiyan, Sooryanarayana Lnu filed Critical The Regents Of The University Of Michigan
Publication of CA2628390A1 publication Critical patent/CA2628390A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
CA002628390A 2005-11-02 2006-11-02 Profilage moleculaire de cancer Abandoned CA2628390A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73285905P 2005-11-02 2005-11-02
US60/732,859 2005-11-02
PCT/US2006/042784 WO2007056049A2 (fr) 2005-11-02 2006-11-02 Profilage moleculaire de cancer

Publications (1)

Publication Number Publication Date
CA2628390A1 true CA2628390A1 (fr) 2007-05-18

Family

ID=38023798

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002628390A Abandoned CA2628390A1 (fr) 2005-11-02 2006-11-02 Profilage moleculaire de cancer

Country Status (3)

Country Link
EP (1) EP1945817A4 (fr)
CA (1) CA2628390A1 (fr)
WO (1) WO2007056049A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008039774A1 (fr) 2006-09-25 2008-04-03 Mayo Foundation For Medical Education And Research Marqueurs associés à une membrane et marqueurs extracellulaires du cancer de la prostate
WO2008058018A2 (fr) 2006-11-02 2008-05-15 Mayo Foundation For Medical Education And Research Prédiction de l'évolution d'un cancer
CA2725978A1 (fr) 2008-05-28 2009-12-03 Genomedx Biosciences, Inc. Systemes et procedes de discrimination basee sur l'expression d'etats pathologiques cliniques distincts dans le cancer de la prostate
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
CA2739140A1 (fr) * 2008-10-01 2010-04-08 Noviogendix Research B.V. Marqueurs moleculaires pour le cancer de la prostate
EP2243843A1 (fr) * 2009-04-24 2010-10-27 Institut Curie HP1ALPHA en tant que marqueur de pronostic dans le cancer humain
WO2013090620A1 (fr) 2011-12-13 2013-06-20 Genomedx Biosciences, Inc. Diagnostics du cancer à l'aide de transcriptions non codantes
DK3435084T3 (da) * 2012-08-16 2023-05-30 Mayo Found Medical Education & Res Prostatakræftprognose under anvendelse af biomarkører
WO2018039490A1 (fr) 2016-08-24 2018-03-01 Genomedx Biosciences, Inc. Utilisation de signatures génomiques en vue d'une prédiction de la réactivité de patients atteints d'un cancer de la prostate à une radiothérapie postopératoire
AU2018210695A1 (en) 2017-01-20 2019-08-08 The University Of British Columbia Molecular subtyping, prognosis, and treatment of bladder cancer
EP3593140A4 (fr) 2017-03-09 2021-01-06 Decipher Biosciences, Inc. Sous-typage du cancer de la prostate pour prédire la réponse à une thérapie hormonale
EP3596467B1 (fr) * 2017-03-16 2023-09-27 Université Libre de Bruxelles Détection, quantification et/ou isolement de cellules tumorales circulantes sur la base de l'expression du marqueur cd321
CA3062716A1 (fr) 2017-05-12 2018-11-15 Decipher Biosciences, Inc. Signatures genetiques pour predire une metastase du cancer de la prostate et identifier la virulence d'une tumeur
CN115436636A (zh) * 2022-11-08 2022-12-06 济南市中心医院 连接粘附分子样蛋白jaml在结直肠癌中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277568B1 (en) * 1998-04-09 2001-08-21 Incyte Genomics, Inc. Nucleic acids encoding human ubiquitin-conjugating enzyme homologs
AUPR278301A0 (en) * 2001-01-31 2001-02-22 Bionomics Limited A novel gene
US6949342B2 (en) * 2001-12-21 2005-09-27 Whitehead Institute For Biomedical Research Prostate cancer diagnosis and outcome prediction by expression analysis
EP1497461A4 (fr) * 2002-04-15 2007-06-06 Rigel Pharmaceuticals Inc Procedes de criblage de modulateurs du cycle cellulaire
WO2005047321A2 (fr) * 2003-11-14 2005-05-26 Creighton University Polynucléotides inhibant l'expression de polypeptides et leurs méthodes d'utilisation

Also Published As

Publication number Publication date
EP1945817A2 (fr) 2008-07-23
EP1945817A4 (fr) 2008-12-10
WO2007056049A3 (fr) 2008-01-31
WO2007056049A2 (fr) 2007-05-18

Similar Documents

Publication Publication Date Title
CA2628390A1 (fr) Profilage moleculaire de cancer
US7803552B2 (en) Biomarkers for predicting prostate cancer progression
AU2002355852B2 (en) Expression profile of prostate cancer
US7598052B2 (en) Expression profile of thyroid cancer
US7700293B2 (en) Expression profile of prostate cancer
US7332290B2 (en) Dectection of AMACR cancer markers in urine
US20070128639A1 (en) Molecular profiling of cancer
US20040063120A1 (en) Expression profile of lung cancer
AU2015360694A1 (en) Use of markers including filamin a in the diagnosis and treatment of prostate cancer
Leman et al. Biomarkers for prostate cancer
US9809859B2 (en) Biomarkers for subtypes of cervical cancer
WO2012125411A1 (fr) Procédés de prédiction du pronostic dans le cancer
Szymonek et al. Immunohistochemistry cannot replace DNA analysis for evaluation of BRAF V600E mutations in papillary thyroid carcinoma
Pacak et al. A novel liquid biopsy (NETest) identifies paragangliomas and pheochromocytomas with high accuracy
EP2707721A1 (fr) Biomarqueurs prédictifs pour le cancer de la prostate
US20100297657A1 (en) Expression profile of prostate cancer
Ramirez et al. Discovery and validation of ovarian cancer biomarkers utilizing high density antibody microarrays
US7951544B1 (en) Method for determining the prognosis of cancer patients by measuring levels of bag expression
US20150191795A1 (en) Raf gene fusions
US20160047000A1 (en) Methods and systems for treatment of ovarian cancer
US20150011411A1 (en) Biomarkers of cancer
US20160138108A1 (en) Stroma biomarkers for the diagnosis of prostate cancer
Zhang et al. High Expression of PPFIA1 Is Associated With Tumor Progression and a Poor Prognosis in Esophageal Squamous Cell Carcinoma
WO2022082317A1 (fr) Signature génique pour prédire la progression et l'évolution des cancers urinaires et procédés d'utilisation associés

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued